Transaction in Own Shares

RNS Number : 5197F

The MedicX Fund Limited

20 February 2015

 

Press Release

For immediate release

20 February 2015

MedicX Fund Limited 

("MedicX Fund", "the Fund" or "the Company")

Transaction in Own Shares

On 18 February 2015, the Company announced that it had issued 32,806,402 new ordinary shares of no par value in the Company (the "Shares") to its broker, Canaccord Genuity Limited ("Canaccord") at the issue price of 83.5p per share (the "Issue Price").  The Company also announced that it intended to repurchase the 32,806,402 Shares issued to Canaccord, into treasury, pursuant to the shareholder authorities granted at the Company's annual general meeting held on 17 February 2015.

Today the Company announces that it has repurchased the 32,806,402 Shares from Canaccord, at the Issue Price.  The Shares will be held in treasury and used by the Company in the future to satisfy demand under the scrip dividend scheme and/or be sold into the market to satisfy general market demand.

Total Voting Rights

Following the buyback, the Company's share capital consists of 394,252,182 ordinary shares, of which 32,806,402 shares are held in treasury.  Accordingly, the number of shares with voting rights in issue is 361,445,780.  This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Enquiries:

MedicX Fund                                                                              [phone]

David Staples, Chairman                                                            

Octopus Healthcare Group                                                          [phone]

Mike Adams, Chief Executive Officer

Mark Osmond, Chief Financial Officer

Canaccord Genuity Limited

Andrew Zychowski/Denis Flanagan                                               [phone]

Buchanan Communications                                                          [phone]

Charles Ryland/Sophie McNulty

Information on MedicX Fund Limited

MedicX Fund Limited ("MXF", the "Fund" or the "Company", or together with its subsidiaries, the "Group") is a specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom, listed on the London Stock Exchange, with a portfolio comprising 141 properties.

The Investment Adviser to the Company is Octopus Healthcare Adviser Ltd, which is authorised and regulated by the Financial Conduct Authority and is a subsidiary of the Octopus Healthcare Group. The Octopus Healthcare Group is a specialist investor, developer and manager of healthcare properties with 36 people operating across the UK. 

The Company's website address is www.medicxfund.com. Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) nor the contents off any website accessible from hyperlinks within this announcement, are incorporated into, or form part of, this announcement.

 

END

 

 

POSLLFLRFTIIFIE